Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Tvardi Therapeutics (TVRD) Gross Profit (2022 - 2024)

Tvardi Therapeutics' Gross Profit history spans 3 years, with the latest figure at $1.5 million for Q4 2024.

  • On a quarterly basis, Gross Profit fell 39.27% to $1.5 million in Q4 2024 year-over-year; TTM through Dec 2024 was $6.5 million, a 55.95% decrease, with the full-year FY2024 number at $6.5 million, down 55.95% from a year prior.
  • Gross Profit hit $1.5 million in Q4 2024 for Tvardi Therapeutics, down from $2.6 million in the prior quarter.
  • Over the last five years, Gross Profit for TVRD hit a ceiling of $23.0 million in Q2 2022 and a floor of $991000.0 in Q2 2024.
  • Historically, Gross Profit has averaged $4.7 million across 3 years, with a median of $2.6 million in 2022.
  • Biggest five-year swings in Gross Profit: soared 111.85% in 2023 and later tumbled 82.03% in 2024.
  • Tracing TVRD's Gross Profit over 3 years: stood at $1.1 million in 2022, then skyrocketed by 111.85% to $2.4 million in 2023, then plummeted by 39.27% to $1.5 million in 2024.
  • Business Quant data shows Gross Profit for TVRD at $1.5 million in Q4 2024, $2.6 million in Q3 2024, and $991000.0 in Q2 2024.